A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Cystic Fibrosis

In brief

The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.

Key facts

Study ID
NCT05668741
Run by
Vertex Pharmaceuticals Incorporated
People needed
26
Starts
2023-02-27
Expected to finish
2026-09-09
Last updated by the study team
2026-05-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.